XML 74 R49.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements (Research Collaborations and In-Licensing Arrangements) (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Jul. 31, 2019
USD ($)
program
May 31, 2019
USD ($)
Oct. 02, 2020
USD ($)
Jan. 01, 2021
USD ($)
Collaborative Arrangement With Catalent        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative agreements upfront payments     $ 10.0  
Collaboration and license agreement target selection term     3 years  
Collaboration and license agreement extended target selection term     5 years  
Collaboration agreements additional upfront payments     $ 4.0  
Collaboration agreement option exercise fee payment, upon exercising option     2.0  
Maximum amount eligible for development and regulatory milestones     44.0  
Maximum amount eligible for commercial milestones under collaborations agreement     60.0  
Collaborative Arrangement With N B E Therapeutics        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaborative agreements upfront payments     $ 25.0  
Collaboration and license agreement target selection term     2 years  
Collaboration and license agreement extended target selection term     3 years  
Collaboration agreements additional upfront payments     $ 2.0  
Collaboration agreement option exercise fee payment, upon exercising option     10.0  
Maximum amount eligible for development and regulatory milestones     90.0  
Maximum amount eligible for commercial milestones under collaborations agreement     $ 135.0  
Extension option term     18 months  
Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Maximum amount eligible for development and regulatory milestones $ 148.8      
Collaboration agreement, number of programs | program 6      
Upfront payments $ 17.5      
Collaboration agreement pre-existing programs | program 3      
Potential development and regulatory milestone payments $ 280.0      
Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Maximum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaboration agreement option exercise fee payment, upon exercising option       $ 12.0
Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Minimum        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaboration agreement option exercise fee payment, upon exercising option       10.0
Collaboration Agreement With Iconic Therapeutics, Inc.        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Collaboration agreement option exercise fee payment, upon exercising option       20.0
Maximum amount eligible for development and regulatory milestones       190.6
Potential development and regulatory milestone payments       $ 262.5
Upfront payment   $ 7.5